| Literature DB >> 29371178 |
Lijing L Yan1,2, Shu Chen1, Enying Gong1, Dhruv S Kazi3,4,5, Ann B Gates6, Rong Bai7,8, Hua Fu9, Weixia Peng9, Ginny De La Cruz1, Lei Chen10, Xianxia Liu10, Qingjie Su11, Nicolas Girerd12,13, Kamilu M Karaye14, Khalid F Alhabib15, J D Schwalm16,17.
Abstract
BACKGROUND: Coronary heart disease (CHD) is the leading cause of cardiovascular mortality worldwide, yet implementation of evidence-based strategies for secondary prevention remains suboptimal.Entities:
Keywords: coronary heart disease; medication adherence; mobile applications; secondary prevention; text messaging
Year: 2018 PMID: 29371178 PMCID: PMC5806005 DOI: 10.2196/mhealth.7849
Source DB: PubMed Journal: JMIR Mhealth Uhealth ISSN: 2291-5222 Impact factor: 4.773
Figure 1The Adherence and Knowledge Exchange heart disease medicines (TAKEmeds) study flowchart.
Figure 2Flowchart of the Adherence and Knowledge Exchange heart disease medicines (TAKEmeds) app operational procedures.
Figure 3Examples of text messages developed and used in the Adherence and Knowledge Exchange heart disease medicines (TAKEmeds) study.
Demographic, health status, and medicine use of patients at baseline.
| Baseline characteristics | Total (N=190) | Shanghai (N=98) | Hainan (N=92) | ||
| Female | 60 (31.6) | 35 (35.7) | 25 (27.2) | .21 | |
| Male | 130 (68.4) | 63 (64.3) | 67 (72.8) | ||
| Age in years, mean (SD) | 67 (10) | 69 (8) | 64 (12) | .004 | |
| Diagnosed with hypertension, n (%) | 114 (60.0) | 70 (71.4) | 44 (47.8) | .001 | |
| Diagnosed with diabetes, n (%) | 49 (25.8) | 28 (28.6) | 21 (22.8) | .34 | |
| MIa | 105 (55.3) | 47 (48.0) | 58 (63.0) | .03 | |
| Non-MI | 85 (44.7) | 51 (52.0) | 34 (37.0) | ||
| Within 1 year | 67 (35.3) | 17 (17.3) | 50 (54.3) | <.001 | |
| More than 1 year | 123 (64.7) | 81 (82.7) | 42 (45.7) | ||
| 1 | 20 (10.5) | 20 (20.4) | 0 | ||
| 2 | 37 (19.5) | 26 (26.5) | 11 (12.0) | <.001 | |
| 3 and more | 133 (70.0) | 52 (53.1) | 81 (88.0) | ||
| ACEb inhibitors and ARBc | 43 (22.6) | 27 (27.6) | 16 (17.4) | .09 | |
| Antiplatelets | 152(80.0) | 67 (68.4) | 85 (92.4) | <.001 | |
| Beta-blockers | 118 (62.1) | 52 (53.1) | 66 (71.7) | .01 | |
| Aldosterone antagonists | 9 (4.7) | 0 | 9 (9.8) | .02 | |
| Statins and other lipid-lowering agents | 131 (68.9) | 59 (60.2) | 72 (78.3) | .01 | |
aMI: myocardial infarction.
bACE inhibitors: angiotensin-converting enzyme inhibitors.
cARB: angiotensin receptor blockers.
Effect of the Adherence and Knowledge Exchange heart disease medicines (TAKEmeds) intervention on the primary outcome: medication adherence.
| Unadjusted ORa
| Adjustedb OR | ||||||
| High | 107 (61.5) | 121 (69.5) | 1.74 (1.09-2.78) | .02 | 1.80 (1.14-2.85) | .01 | |
| Middle | 44 (25.3) | 44 (25.3) | |||||
| Low | 23 (13.2) | 9 (5.2) | |||||
| High | 61 (64.9) | 47 (50.0) | 0.71 (0.42-1.22) | .22 | 0.61 (0.33-1.12) | .11 | |
| Middle | 19 (20.2) | 38 (40.4) | |||||
| Low | 14 (14.9) | 9 (9.6) | |||||
| High | 46 (57.5) | 74 (92.5) | 12.85 (4.62-35.76) | <.001 | 14.68 (5.20-41.45) | <.001 | |
| Middle | 25 (31.3) | 6 (7.5) | |||||
| Low | 9 (11.3) | 0 | |||||
aOR: Odds ratio.
bAdjusted for age, gender, region, heart disease type, heart disease diagnosis time (< or >1 year), hypertension, diabetes status, and number of medications taken.
Paired pre-post comparison of secondary outcomes.
| Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | |||||
| Highly activea | 14 (8.0) | 17 (9.7) | .91 | 7 (7.4) | 8 (8.4) | .36 | 7 (8.6) | 9 (11.1) | .57 | |
| Minimally activeb | 112 (63.6) | 105 (59.7) | 69 (72.6) | 62 (65.3) | 43 (53.1) | 43 (53.1) | ||||
| Inactivec | 50 (28.4) | 54 (30.7) | 19 (20.0) | 25 (26.3) | 31 (38.3) | 29 (35.8) | ||||
| Everyday | 18 (10.2) | 13 (7.4) | .05 | 8 (8.4) | 3 (3.2) | .06 | 10 (12.3) | 10 (12.3) | .36 | |
| Seldom | 12 (6.8) | 9 (5.1) | 6 (6.3) | 8 (8.4) | 6 (7.4) | 1 (1.2) | ||||
| Never | 146 (83.0) | 154 (87.5) | 81 (85.3) | 84 (88.4) | 65 (80.2) | 70 (86.4) | ||||
| Fruits consumption, median frequency/ day | 0.5 | 0.6 | .18 | 0.6 | 0.8 | .65 | 0.3 | 0.6 | .17 | |
| Vegetable consumption, median frequency/day | 2.4 | 2.7 | .01 | 2.6 | 3.2 | .001 | 1.8 | 2.2 | .73 | |
| Facility visit, median frequency/3 months | 3 | 3 | .22 | 7 | 10 | .04 | 1 | 2 | .69 | |
aVigorous-intensity activity on at least 3 days, achieving a minimum of at least 1500 metabolic equivalent (MET)-minutes per week, OR 7 or more days of any combination of walking, moderate-intensity, or vigorous-intensity activities, achieving a minimum of at least 3000 MET-minutes per week.
b3 or more days of vigorous activity for at least 20 min per day OR 5 or more days of moderate-intensity activity or walking for at least 30 min per day OR 5 or more days of any combination of walking, moderate-intensity, or vigorous-intensity activities, achieving a minimum of at least 600 MET-min per week.
cIndividuals who do not meet criteria for the above 2 categories are considered inactive.
Perceived helpfulness of the intervention program and user feedback.
| Characteristics | Total, n (%) | Shanghai, n (%) | Hainan, n (%) | |
| Medication adherence (n=152) | 123 (80.9) | 68 (74.7) | 55 (90.2) | |
| Healthy diet (n=173) | 132 (76.3) | 69 (75.8) | 63 (76.8) | |
| Exercise (n=173) | 115 (66.5) | 53 (58.2) | 62 (75.6) | |
| Smoking cessation (n=23) | 14 (60.9) | 3(30.0) | 11 (84.6) | |
| Communication with physicians (n=173) | 129 (74.6) | 59 (64.8) | 70 (85.4) | |
| Text messages | 111 (64.9) | 84 (92.3) | 27 (33.8) | |
| Voice calls | 57 (33.3) | 4 (4.4) | 53 (66.3) | |
| Other | 3 (1.8) | 3 (3.3) | 0 | |
| 8:00-11:59 AM | 73 (42.2) | 40 (44.0) | 33 (40.2) | |
| 12:00-12:59 PM | 3 (1.7) | 2 (2.2) | 1 (1.2) | |
| 1:00-4:59 PM | 14 (8.1) | 5 (5.5) | 9 (11.0) | |
| 5:00-9:00 PM | 24 (13.9) | 9 (9.9) | 15 (18.3) | |
| Does not matter | 59 (34.1) | 35 (38.5) | 24 (29.3) | |
| ≥Twice/day | 3 (1.8) | 2 (2.2) | 1 (1.3) | |
| Once/day | 42 (24.6) | 31 (34.1) | 11 (13.8) | |
| 5-6 times/week | 8 (4.7) | 6 (6.6) | 2 (2.5) | |
| 3-4 times/week | 17 (9.9) | 9 (9.9) | 8 (10.0) | |
| 1-2 times/week | 68 (39.8) | 29 (31.9) | 39 (48.8) | |
| 1-3 times/month | 33 (19.3) | 14 (15.4) | 19 (23.8) | |
| One-way only | 59 (34.7) | 46 (50.5) | 13 (16.5) | |
| Two-way | 111 (65.3) | 45 (49.5) | 66 (83.5) | |
| Satisfaction toward the program (n=172) | 153 (89.0) | 75 (82.4) | 78 (96.3) | |